Augustina Isioma Ikusemoro: Kell vs RhD Sensitization – The Difference in RBC Destruction
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Anti-D destroys red cells.
Anti-K stops them from being made.
That difference can change everything in fetal survival.
Most clinicians are trained to recognize RhD sensitization as a major cause of Hemolytic Disease of the Fetus and Newborn (HDFN).
But fewer appreciate that Kell sensitization can be equally — and sometimes more — dangerous.
Here’s why this matters
While RhD antibodies destroy circulating fetal red blood cells, Anti-K antibodies suppress fetal red cell production at the bone marrow level.
This means:
- RhD sensitization leads to hemolysis
- Kell sensitization leads to erythropoiesis suppression
And clinically, that distinction is critical.
In RhD HDFN, anemia develops because red cells are destroyed in the fetal spleen.
In Kell-mediated HDFN, anemia develops because red cells are never produced in adequate numbers in the first place.
The result?
- Earlier onset anemia
- Lower reticulocyte counts
- Less predictable disease progression
- Severe fetal compromise even with low antibody titers
Unlike RhD disease — where bilirubin levels often reflect severity — Kell disease can progress silently until fetal anemia becomes critical.
This is why Anti-K detection during pregnancy must always trigger enhanced fetal surveillance.
And why transfusion services must prioritize:
- K- antigen matching for sensitized patients
- Prevention of alloimmunization in women of child-bearing age
- Extended phenotype awareness beyond ABO and RhD
Because transfusion safety doesn’t stop at compatibility.
It continues with anticipation.
Blood Doki
Advancing transfusion safety through education, systems awareness, and clinical insight.”

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 03:45Aref Ghanaatpisheh: The Role of Systemic Inflammation in Preoperative Deep Vein Thrombosis Risk Assessment
-
Nov 21, 2026, 03:43Dimitrios Hatzichristou: Advancing Standardization and Quality Control in Platelet-Rich Plasma Therapy
-
Nov 21, 2026, 03:15Amirabbas Sheykhalo: Silent Mesenteric Ischemia in Portomesenteric Thrombosis
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan